Virtual AACC
Highlights from laboratory diagnostics that have a strong impact on the industry
2020 was an unprecedented year for in vitro diagnostics. Although a large number of medical decisions have always been based on diagnostic tests, the need for laboratory diagnostic procedures has never been greater in the face of the pandemic. Against this background, this year's AACC Annual Scientific Meeting & Clinical Lab Expo from December 13 to 17, which took place virtually for the first time in its history, presented highly automated solutions that minimize contact and increase laboratory efficiency and safety. The congress was closely accompanied by the Siemens Healthineers Shape 21 Forum
1 Product and service availability varies by country
2 Product and service availability varies by country
3 These SARS-CoV-2 molecular and serology tests have not been FDA cleared or approved. These tests have been authorized by FDA under an EUA for use by authorized laboratories. The molecular test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The serology test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary from country to country and is subject to varying regulatory requirements.
4 Claims for neutralizing antibody detection have not been reviewed by FDA and are not available for use in the U.S.
5 POC Rapid Tests are distributed by Siemens Healthineers. Not available for sale in the U.S. Product availability varies by country.
6 Product availability varies by country.